Akili has submitted its digital therapeutic SDT-001 for marketing approval with the Japanese Ministry of Health, Labour, and Welfare as a treatment for ADHD.
The digital therapeutic is a localised version of AKL-T01, which is marketed as EndeavorRx in the US. EndeavorRx was approved as the first prescription digital therapeutic by the FDA for improving attentional functioning in paediatric patients (aged 8-17 years) with ADHD in 2020.
Following the news of the Japanese expansion, the company’s stock rose by 192.8% at market open on 26 February, compared to market close on 23 February. Akili’s market cap stands at $35.42m.
Shionogi holds the commercialisation rights to the ADHD digital therapeutic in Japan and Taiwan as part of a 2019 collaboration agreement. Under the terms of the partnership, Akili will be entitled to royalties on sales of SDT-001 in the region.
Concurrent with the marketing approval submission, Akili also released the Phase III trial data that was submitted as part of the application. Shionogi conducted the Phase III trial that evaluated the efficacy and safety of SDT-001 in 164 paediatric ADHD patients aged 6-17 years. Following once-daily treatment with SDT-001 for six weeks, the study met its primary endpoint by demonstrating an improvement in the Attention Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Inattention score compared to the control group.
The participants in the SDT-001 treatment group also showed an improvement in the hyperactivity/impulsivity score at six weeks, compared to the control. The improvement in symptoms was sustained with six additional weeks of therapy. No serious side effects were reported during the trial.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
According to the EndeavorRx website, the digital therapeutic uses sensory stimuli and motor challenges to target areas of the brain that play a key role in attention function. Children are challenged to multitask and ignore distractions by navigating courses, collecting targets, and avoiding obstacles. It is recommended to play for no more than 25 minutes, five days a week for at least four consecutive weeks, or as prescribed.
GlobalData has identified digital therapeutics as a growing sector in healthcare. The US digital therapeutics is projected to grow at a compound annual growth rate (CAGR) of 25% from 2022 to 2030. However, reimbursement of these therapies is expected to slow the adoption of these therapies, as per a GlobalData report.
<!– –>
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.medicaldevice-network.com/news/akili-prepares-for-japan-launch-of-adhd-gaming-therapy/
